KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Invested Capital (2016 - 2025)

Historic Invested Capital for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $917.3 million.

  • Acadia Pharmaceuticals' Invested Capital rose 5892.3% to $917.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $917.3 million, marking a year-over-year increase of 5892.3%. This contributed to the annual value of $732.8 million for FY2024, which is 6972.43% up from last year.
  • Acadia Pharmaceuticals' Invested Capital amounted to $917.3 million in Q3 2025, which was up 5892.3% from $822.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Invested Capital high stood at $917.3 million for Q3 2025, and its period low was $362.2 million during Q3 2023.
  • Its 5-year average for Invested Capital is $543.1 million, with a median of $516.7 million in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 2597.2% in 2022, then skyrocketed by 6972.43% in 2024.
  • Acadia Pharmaceuticals' Invested Capital (Quarter) stood at $540.9 million in 2021, then dropped by 25.97% to $400.4 million in 2022, then rose by 7.83% to $431.8 million in 2023, then soared by 69.72% to $732.8 million in 2024, then increased by 25.17% to $917.3 million in 2025.
  • Its last three reported values are $917.3 million in Q3 2025, $822.4 million for Q2 2025, and $765.2 million during Q1 2025.